vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and IMAX CORP (IMAX). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $125.2M, roughly 1.1× IMAX CORP). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 0.5%, a 35.0% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 18.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $28.0M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 25.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
ADMA vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $125.2M |
| Net Profit | $49.4M | $637.0K |
| Gross Margin | 63.8% | 57.6% |
| Operating Margin | 45.1% | 19.3% |
| Net Margin | 35.5% | 0.5% |
| Revenue YoY | 18.4% | 35.1% |
| Net Profit YoY | -55.9% | -88.0% |
| EPS (diluted) | $0.20 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $125.2M | ||
| Q3 25 | $134.2M | $106.7M | ||
| Q2 25 | $122.0M | $91.7M | ||
| Q1 25 | $114.8M | $86.7M | ||
| Q4 24 | $117.5M | $92.7M | ||
| Q3 24 | $119.8M | $91.5M | ||
| Q2 24 | $107.2M | $89.0M | ||
| Q1 24 | $81.9M | $79.1M |
| Q4 25 | $49.4M | $637.0K | ||
| Q3 25 | $36.4M | $20.7M | ||
| Q2 25 | $34.2M | $11.3M | ||
| Q1 25 | $26.9M | $2.3M | ||
| Q4 24 | $111.9M | $5.3M | ||
| Q3 24 | $35.9M | $13.9M | ||
| Q2 24 | $32.1M | $3.6M | ||
| Q1 24 | $17.8M | $3.3M |
| Q4 25 | 63.8% | 57.6% | ||
| Q3 25 | 56.3% | 63.1% | ||
| Q2 25 | 55.1% | 58.5% | ||
| Q1 25 | 53.2% | 61.4% | ||
| Q4 24 | 53.9% | 52.2% | ||
| Q3 24 | 49.8% | 55.8% | ||
| Q2 24 | 53.6% | 49.4% | ||
| Q1 24 | 47.8% | 59.3% |
| Q4 25 | 45.1% | 19.3% | ||
| Q3 25 | 38.0% | 27.2% | ||
| Q2 25 | 35.1% | 15.6% | ||
| Q1 25 | 30.4% | 19.3% | ||
| Q4 24 | 32.6% | 10.3% | ||
| Q3 24 | 33.1% | 21.2% | ||
| Q2 24 | 36.6% | 3.2% | ||
| Q1 24 | 26.7% | 15.3% |
| Q4 25 | 35.5% | 0.5% | ||
| Q3 25 | 27.1% | 19.4% | ||
| Q2 25 | 28.1% | 12.3% | ||
| Q1 25 | 23.4% | 2.7% | ||
| Q4 24 | 95.2% | 5.7% | ||
| Q3 24 | 30.0% | 15.2% | ||
| Q2 24 | 29.9% | 4.0% | ||
| Q1 24 | 21.7% | 4.1% |
| Q4 25 | $0.20 | $0.02 | ||
| Q3 25 | $0.15 | $0.37 | ||
| Q2 25 | $0.14 | $0.20 | ||
| Q1 25 | $0.11 | $0.04 | ||
| Q4 24 | $0.45 | $0.09 | ||
| Q3 24 | $0.15 | $0.26 | ||
| Q2 24 | $0.13 | $0.07 | ||
| Q1 24 | $0.08 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $151.2M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $337.9M |
| Total Assets | $624.2M | $894.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $151.2M | ||
| Q3 25 | $61.4M | $143.1M | ||
| Q2 25 | $90.3M | $109.3M | ||
| Q1 25 | $71.6M | $97.1M | ||
| Q4 24 | $103.1M | $100.6M | ||
| Q3 24 | $86.7M | $104.5M | ||
| Q2 24 | $88.2M | $91.6M | ||
| Q1 24 | $45.3M | $81.0M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $337.9M | ||
| Q3 25 | $431.2M | $349.5M | ||
| Q2 25 | $398.3M | $320.4M | ||
| Q1 25 | $373.4M | $299.5M | ||
| Q4 24 | $349.0M | $299.5M | ||
| Q3 24 | $231.9M | $289.4M | ||
| Q2 24 | $188.3M | $267.2M | ||
| Q1 24 | $153.7M | $258.8M |
| Q4 25 | $624.2M | $894.0M | ||
| Q3 25 | $568.7M | $889.6M | ||
| Q2 25 | $558.4M | $868.6M | ||
| Q1 25 | $510.6M | $848.3M | ||
| Q4 24 | $488.7M | $830.4M | ||
| Q3 24 | $390.6M | $847.6M | ||
| Q2 24 | $376.4M | $827.4M | ||
| Q1 24 | $350.9M | $824.1M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $29.4M |
| Free Cash FlowOCF − Capex | $34.6M | $28.0M |
| FCF MarginFCF / Revenue | 24.8% | 22.3% |
| Capex IntensityCapex / Revenue | 0.8% | 1.1% |
| Cash ConversionOCF / Net Profit | 0.72× | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $29.4M | ||
| Q3 25 | $13.3M | $67.5M | ||
| Q2 25 | $21.1M | $23.2M | ||
| Q1 25 | $-19.7M | $7.0M | ||
| Q4 24 | $50.2M | $11.5M | ||
| Q3 24 | $25.0M | $35.3M | ||
| Q2 24 | $45.6M | $35.0M | ||
| Q1 24 | $-2.2M | $-11.0M |
| Q4 25 | $34.6M | $28.0M | ||
| Q3 25 | $-1.1M | $64.8M | ||
| Q2 25 | $18.7M | $20.9M | ||
| Q1 25 | $-24.4M | $5.3M | ||
| Q4 24 | $47.5M | $6.9M | ||
| Q3 24 | $24.0M | $34.2M | ||
| Q2 24 | $43.6M | $33.5M | ||
| Q1 24 | $-4.6M | $-12.1M |
| Q4 25 | 24.8% | 22.3% | ||
| Q3 25 | -0.8% | 60.7% | ||
| Q2 25 | 15.3% | 22.8% | ||
| Q1 25 | -21.2% | 6.1% | ||
| Q4 24 | 40.4% | 7.4% | ||
| Q3 24 | 20.0% | 37.3% | ||
| Q2 24 | 40.7% | 37.6% | ||
| Q1 24 | -5.6% | -15.3% |
| Q4 25 | 0.8% | 1.1% | ||
| Q3 25 | 10.7% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 4.1% | 1.9% | ||
| Q4 24 | 2.3% | 5.0% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 1.9% | 1.8% | ||
| Q1 24 | 2.9% | 1.4% |
| Q4 25 | 0.72× | 46.11× | ||
| Q3 25 | 0.36× | 3.27× | ||
| Q2 25 | 0.62× | 2.06× | ||
| Q1 25 | -0.73× | 2.99× | ||
| Q4 24 | 0.45× | 2.16× | ||
| Q3 24 | 0.70× | 2.54× | ||
| Q2 24 | 1.42× | 9.78× | ||
| Q1 24 | -0.12× | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
